Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial. (PubMed, Eur J Cancer) - Sep 24, 2026 - P2 | "Low baseline MLR and positive CPS identified patients with particular benefit from FLOT + nivo that may outweigh the enhanced burden of intensified therapy."
Biomarker • IO biomarker • Journal • P2 data • Fatigue • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Pain • Solid Tumor • PD-L1
|
|
Alexander Nieto; Alexander Stein; Claudia Pauligk; Claus Bolling; Daniel Pink; Eray Goekkurt; Gunnar Folprecht; Gunter Schuch; Jorge Riera-Knorrenschild; Joseph Tintelnot; Kim Barbara Luley; Maria Loose; Michael Bitzer; Michael Masetti; Peter C Thuss-Patience; Ralf Dieter Hofheinz; Sabine Junge; Salah-Eddin Al-Batran; Stefan Angermeier; Sylvie Lorenzen; Thomas Jens Ettrich; Thorsten Oliver Goetze; Tobias Nicolaas Dechow; Udo Lindig; Volker Heinemann
|